1. Introduction {#S1}
===============

Numerous studies have demonstrated the relationship between structural and compositional features and antioxidative capacity of high-density lipoprotein (HDL) \[[@R1],[@R2]\]. The well-established capacity of HDL to inactivate lipid hydroperoxides (LOOH) and protect low-density lipoprotein (LDL) from oxidation is largely determined by the HDL content of apolipoprotein A-I (apoA-I) and the oxidative status of apoA-I methionine (Met) residues \[[@R3]\]. ApoA-I mediates both the removal of LOOH molecules from LDL as well as the reduction of HDL-associated LOOH to redox-inactive lipid hydroxides \[[@R4]\]. Other HDL-associated apolipoproteins and enzymes such as paraoxonase 1 (PON1), platelet-activated factor-acetylhydrolase (PAF-AH), and lecithin:cholesterol acyltransferase (LCAT) also contribute to the antioxidative capacity of HDL \[[@R1],[@R5]\].

Besides HDL proteins, HDL lipids also shape the antioxidative capacity of HDL \[[@R6]\]. This is primarily due to the impact of lipids on the fluidity of the HDL surface and on the size of the HDL core. For example, enrichment of HDL with ceramide, sphingomyelin or cholesterol decreases the antioxidative capacity of HDL. This is thought to be due to a decreased HDL surface fluidity and in consequence reduced transfer of LOOH from LDL to HDL \[[@R7]\]. The antioxidative capacity of HDL is also affected by alterations in triacylglycerol (TAG) and cholesteryl ester (CE) levels in the HDL core, whereby an increased TAG content diminishes apoA-I mediated inactivation of LOOH \[[@R8],[@R9]\].

Endothelial lipase (EL) is a strong negative regulator of HDL plasma levels \[[@R10]\] and a potent modulator of HDL lipid composition \[[@R11],[@R12]\]. EL belongs to the TAG lipase family and is mainly synthesized and secreted by vascular endothelial cells \[[@R13],[@R14]\]. By its pronounced phospholipase activity EL depletes HDL phospholipids (PL) thereby producing lysophospholipids (LysoPL) and fatty acids (FA) \[[@R15]\]. EL-mediated depletion of HDL-PL alters structural and functional properties of HDL \[[@R11],[@R16]\]. However, the role of EL in atherosclerosis still remains inconclusive: in one study EL promoted the progression of atherosclerosis in apolipoprotein E (apoE)-deficient mice \[[@R17]\], whereas in another study EL had no impact on atherosclerosis development in apoE- or LDL receptor-deficient mice \[[@R18]\]. Similarly inconclusive data have been published on the impact of EL on the antioxidative capacity of HDL: augmented antioxidative capacity of HDL isolated from EL deficient mice was observed in one \[[@R19]\] but not in another study \[[@R20]\].

The overall antioxidative capacity of HDL as well as the relative contribution of HDL-associated proteins and lipids to the antioxidative capacity of HDL are largely determined by the composition and size of HDL particles \[[@R1]\]. Considering this point as well as the pronounced EL-mediated alterations in HDL structure and composition \[[@R11],[@R12],[@R16]\], we hypothesized that EL may alter the antioxidative capacity of HDL. Therefore, the present study has been designed to investigate the relationship between the composition, structure and antioxidative capacity of *in vitro* generated EL-modified HDL (EL-HDL).

2. Materials and methods {#S2}
========================

2.1. Cell culture {#S3}
-----------------

HepG2 cells (ATCC^®^, HB-8065™) were cultured in DMEM supplemented with 2 mmol/L glutamine, 1% PS (100 U/mL penicillin, 100 μg/mL streptomycin) and 10% fetal calf serum (FCS).

2.2. Human plasma {#S4}
-----------------

Normolipidemic plasma of 18 healthy donors (whose identity was not disclosed to the researcher) was purchased from the blood bank of the Medical University of Graz. The mean donor age was 44.8 ± 11.6 years, with a range of 24--65, and 3 out of 18 donors were female. The regular written informed consent for blood donation covers the donation of residual material for research purposes. The ethics committee of the Medical University of Graz has no objections to the use of the anonymized material for research purposes.

2.3. Isolation of HDL from human plasma {#S5}
---------------------------------------

HDL preparation from human plasma was performed by a one-step density gradient ultracentrifugation method using long centrifuge tubes (16 × 76 mm; Beckman), as described \[[@R21]\]. Briefly, the density-adjusted plasma (1.24 g/mL with potassium bromide) was layered underneath a potassium bromide-density solution (1.063 *g*/mL). Samples were centrifuged at 330,000 ×*g* for 6 h (centrifuge: Beckman Optima L-80 ultracentrifuge, rotor: Sorvall T-1270). Subsequently, the collected HDL was concentrated by Viva Spin Tubes (Sartorius, Vienna, Austria), desalted by gel filtration on Sephadex PD-10 columns (GE Healthcare, Munich, Germany) and stored at −80 °C for further experiments.

2.4. Preparation of EL-HDL and control EV-HDL {#S6}
---------------------------------------------

HepG2 cells (2 × 10^6^) were plated onto 60 mm dishes and incubated under standard conditions as described in [Section 3.1](#S21){ref-type="sec"}. After 24 h, cells were washed once with DMEM without FCS and infected with multiplicity of infection (MOI) 10 of adenovirus encoding human EL (EL-Ad) or empty adenovirus containing no recombinant cDNA (EV-Ad) \[[@R22]\] in DMEM without FCS for 2 h. After removal of infection media, cells were incubated with fresh DMEM containing 10% FCS for 28 h. Thereafter, cells were washed once with DMEM without FCS and each plate was incubated under cell culture conditions with 2 mg HDL protein, re-suspended in 1.8 mL DMEM without FCS, in the absence or presence of 4% (final concentration) of non-esterified fatty acid (NEFA)- free bovine serum albumin (BSA) (Sigma-Aldrich, Vienna, Austria) for 16 h. After incubation, the media were collected and spun at 1100 ×*g* for 3 min to remove cellular debris. EL-HDL and EV-HDL were isolated from media by density gradient ultracentrifugation, desalted and purified by fast protein liquid chromatography (FPLC) as described in [Section 3.9](#S29){ref-type="sec"}.

2.5. Lysophosphatidylcholine (LPC) enrichment of HDL {#S7}
----------------------------------------------------

Enrichment of HDL with LPC was performed as described in our previous study \[[@R23]\]. Required amounts of LPC, which were stored dissolved in chloroform/methanol at −20 °C under argon atmosphere, were dried under a stream of nitrogen and re-dissolved in PBS. The lipolytic products-depleted EL-HDL and EV-HDL (1 mg/mL) (generated in the presence of 4% BSA) were incubated with 0.6 mmol/L LPC 16:0 or 18:1 at 37 °C for 2 h. Unbound LPC were removed by gel filtration. The efficiency of LPC enrichment was examined by mass spectrometry as described in [Section 3.6](#S26){ref-type="sec"}.

2.6. Non-denaturing gradient-gel electrophoresis {#S8}
------------------------------------------------

Non-denaturing gradient-gel electrophoresis of HDL and FPLC fractions was performed as previously described \[[@R16]\]. Briefly, aliquots of HDL (10 μg) and FPLC fractions (15 μL) were electrophoresed on 4--16% non-denaturing polyacrylamide gels upon dilution with native sample buffer (LifeTechnologies, Vienna, Austria) at 125 V for 4 h at room temperature. Gels were stained with Sudan black (Sigma-Aldrich, Vienna, Austria) or fixed with 10% sulfosalicylic acid for 30 min and then stained with Coomassie Brillant Blue G250 or used for Western blotting analysis. The high molecular weight marker NativeMark (LifeTechnologies, Vienna, Austria) was used as standard.

2.7. Targeted lipidomic analysis {#S9}
--------------------------------

Three hundred μg HDL protein were transferred to 2 mL Safe-Lock PP-tubes and extracted according to Matyash et al. \[[@R24]\]. In brief, samples were homogenized using two 6 mm steal beads on a Mixer Mill (Retsch, Haan, GER; 2x15sec, frequency 30/s) in 700 μL MTBE/MeOH (3/1, *v*/v) containing 500 pmol butylated hydroxytoluene, 1% acetic acid, and 100 pmol of internal standards (ISTD, 17:0--17:0 PC, 12:0--12:0 PC, 12:0--12:0 PE, 17:0--17:0 PA, 17:0 FA, d18:1/17:0 Cer, 14:0--14:0 DG, 17:0 LPC, 17:0--17:0--17:0 TG, 15:0--15:0--15:0 TG, Avanti Polar Lipids) per sample. Total lipid extraction was performed under constant shaking for 60 min at RT. After addition of 140 μL dH~2~O and further incubation for 30 min at RT, samples were centrifuged at 1000 ×*g* for 15 min to establish phase separation. Five hundred μL of the upper, organic phase were collected and dried under a stream of nitrogen. Lipids were resolved in 250 μL 2-propanol/methanol/water (7/2.5/1, *v*/v/v) for UPLC-QqQ analysis. Chromatographic separation was modified according to Knittelfelder et al. \[[@R25]\] using an AQUITY-UPLC system (Waters Corporation), equipped with a Kinetex EVOC18 column (2.1 × 50 mm, 1.7 μm; Phenomenex) starting a 25 min gradient with 100% solvent A (MeOH/H~2~O, 1/1, *v*/v; 10 mM ammonium acetate, 0.1% formic acid). A EVOQ Elite™ triple quadrupole mass spectrometer (Bruker) equipped with an ESI source was used for detection. Lipid species were analyzed by selected reaction monitoring (PC: \[MH\] + to *m*/*z* 184, 25 eV, PE: \[MH\] + to -*m*/*z* 141, 20 eV, PI: \[MH\] to corresponding \[FA\]-, 50 eV, LPC: \[MH\] + to *m*/*z* 184, 22 eV, LPE: \[MH\] + to -m/z 141, 17 eV, Cer: \[MH\] + to m/z 264, 22 eV, TG: \[MNH4\] + to corresponding \[DG-H2O\]+, 22 eV, DG: \[MNH4\] + to \[RCOO+58\]+, 15 eV, CE: \[MNH4\] + to m/z 369, FC: \[M-H2O\]+, 0 eV, FA: \[M-H\]-, 0 eV, SM: \[MH\] + to m/z 184, 23 eV). Data acquisition was done by MS Workstation (Bruker). Data were normalized for recovery, extraction-, and ionization efficacy by calculating analyte/ISTD ratios (AU) and expressed as AU/mg protein.

2.8. Small-angle X-ray scattering (SAXS) {#S10}
----------------------------------------

SAXS data for suspensions of HDL were recorded on an in-house SAXS instrument (SAXSess mc2, Anton Paar, Graz, Austria) equipped with a Kratky camera, a sealed X-ray tube source and a two-dimensional Princeton Instruments PI•SCX:4300 (Roper Scientific) CCD detector. The scattering patterns were measured with a 90-min exposure time (540 frames, each 10 s) for several solute concentrations in the range from 0.5 to 1.0 mg/mL. Radiation damage was excluded based on a comparison of individual frames of the 90-min exposures, with no detectable changes. A range of momentum transfer of 0.012 \< s \< 0.63 Å^−1^ was covered (s = 4π sin(θ)/λ, with 2θ scattering angle and λ = 1.5 Å X-ray wavelength). All SAXS data were analyzed with the package ATSAS (version 2.5). The data were processed with the SAXSQuant software (version 3.9) and desmeared using the programs GNOM and GIFT \[[@R26]\]. The forward scattering, I(0), the radius of gyration, Rg, the maximum dimension, D~max~, and the inter-atomic distance distribution functions, (P(R)), were computed with the program GNOM and GIFT. The masses of the solutes were evaluated by comparison of the forward scattering intensity with human serum albumin reference solution (molecular mass 69 kDa) and using the Porod\'s law. To generate *ab initio* shape models, a total number of 50 models were calculated using the program DAMMIF \[[@R27]\] and aligned, and averaged using the program DAMCLUST.

2.9. Negative stain electron microscopy for HDL visualization {#S11}
-------------------------------------------------------------

Glow discharged carbon coated copper grids were used. The grids were placed on 100 μL of HDL suspension (0.8 mg/mL HDL protein) on parafilm for 1 min. The specimens were washed three times with 200 μL water. Samples were blotted with filter paper and placed on a drop of 2% aqueous uranyl acetate solution for 1 min, blotted with filter paper and air dried at room temperature \[[@R28]\]. Specimens were examined with an FEI Tecnai G 2 equipped with an ultrascan 1000 CCD camera (Gatan).

2.10. FPLC of native (nHDL) and modified HDL {#S12}
--------------------------------------------

FPLC was performed as described in our previous report \[[@R29]\]. Briefly, an ÄKTA pure FPLC System (GE Healthcare, Munich, Germany) equipped with a Superdex 200 Increase 10/300 column (GE Healthcare, Munich, Germany) was used with PBS as mobile phase. After loading, HDL samples were separated with a constant flow of 0.5 mL/min, and 0.5 mL fractionation between of 9 to 13.5 mL elution volume were collected. The software UNICORN (GE Healthcare, Munich, Germany) was used for analysis.

2.11. SDS-PAGE and Western blotting {#S13}
-----------------------------------

Preparation of heparin media and analyses of EL overexpression were performed as described \[[@R22]\]. HDL-associated proteins (10 μg) and cell lysates (30 μg) were separated by 12% SDS-PAGE at 175 V for 90 min. Separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Carl Roth, Karlsruhe, Germany) with blotting buffer (Tris, glycine, EDTA, sodium azide) at 150 mA for 90 min. Membranes were blocked at RT in 10% skim milk for 2 h followed by overnight incubation at 4 °C with antibodies specific for: human PON1 (Abcam, ab24261, Cambridge, UK), human apoA-I (Novus biological, NB100--65491, Littleton, CO, USA, or Academy biomedical, 11A-G2b, Houston, TX, USA), human LCAT (Novus biological, Littleton, CO, USA), human PAF-AH (Cayman chemical, 160603, Ann Arbor, MI, USA), α-tubulin (Cell signaling technology, 11H10, Leiden, Netherlands) and albumin (Abcam, ab 83465, Cambridge, UK). After washing and incubation with the appropriate secondary antibody (Dako, Vienna, Austria), protein signals were visualized by incubation with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Schwerte, Germany) using the ChemiDoc system (Bio-Rad Laboratories, Vienna, Austria).

2.12. LDL preparation and oxidation {#S14}
-----------------------------------

Human LDL was isolated from plasma as described previously \[[@R30]\]. LDL was dialyzed against PBS (pH 7.4) without EDTA and diluted to a final concentration of 0.3 mg apoB/mL. Oxidation was performed by addition of a CuCl~2~ solution giving a final concentration of 10 μmol/L. After 4 h oxidation was stopped with EDTA (200 μmol/L) and the LDL was dialyzed against PBS (GIBCO, Life technologies, pH 7.40).

2.13. Kinetics of lipoprotein oxidation (conjugated dienes formation) {#S15}
---------------------------------------------------------------------

Copper ion-induced formation of conjugated dienes was examined as described \[[@R31]\]. Briefly, CuCl~2~ (2 μmol/L) was added to the indicated concentrations of lipoproteins and the formation of conjugated dienes was continuously monitored at 234 nm by a spectrophotometer (Hitachi U-2000) at 37 °C for 100 min. The lag phase was determined with a simple sigmoidal model. The mathematical properties of the model were determined using the software package MATHEMATICA version 11 (Wolfram Research Inc., Champaign, IL, USA) and implemented in a Microsoft EXCEL sheet for convenient usage.

2.14. Malondialdehyde (MDA) analysis {#S16}
------------------------------------

MDA content was measured in the reaction mixtures described in [Section 2.13](#S15){ref-type="sec"}. at termination of the oxidation (120 min), using a HPLC method described by Pilz et al. \[[@R32]\] after derivatization with 2,4-dinitrophenylhydrazine (DNPH). The slight modifications of the method have been reported \[[@R33]\]. Briefly, for alkaline hydrolysis of protein-bound MDA, 25 μL of 6 mol/L sodium hydroxide was added to 0.125 mL of the samples (1.5 mL Eppendorf tubes) and incubated at 60 °C for 30 min. The hydrolyzed sample was deproteinized with 62.5 μL 35% (*v*/v) perchloric acid. The supernatant (125 μL) obtained after centrifugation (14,000 *g*; 2 min) was mixed with 12.5 μL DNPH solution and incubated for 10 min. This reaction mixture, diluted derivatized standard solutions (0.625 nmol/mL -- 10 nmol/mL) and reagent blanks were injected into the HPLC system (injection volume: 40 μL). The MDA standard was prepared by dissolving 25 μL 1,1,3,3-tetramethoxypropane (TMP) in 100 mL bidistilled H~2~O (stock solution: 1 mmol/L). The hydrolysis was performed with 200 μL TMP stock solution in 10 mL 1% sulfuric acid and incubation for 2 h at RT \[[@R34]\].The resulting MDA standard of 20 nmol/mL was further diluted with 1% sulfuric acid to the final concentrations. The DNPH derivaives (hydrazones) were isocratically separated on a 5-μm ODS hypersil column (150 × 4.6 mm) guarded by a 5-μm ODS hypersil column (10 × 4.6 mm; Uniguard holder) with a mobile phase consisting of a 0.2% (*v*/v) acetic acid solution (bidistilled water) containing 50% acetonitrile (v/v) at a flow rate of 0.8 mL/min. The HPLC separations were performed with an L-2200 autosampler (injection volume: 40 μL), a L-2130 HTA pump and a L-2450 diode array detector (all: VWR Hitachi Vienna; Austria). Detector signals (absorbance at 310 nm) were recorded and the program EZchrom Elite (VWR) was used for data requisition and analysis.

2.15. Oxidation of HDL Met residues {#S17}
-----------------------------------

Blocking of Met residues was performed as described previously \[[@R3]\]. Shortly, FPLC-purified EV-HDL and EL-HDL (1.5 mg protein/mL) were incubated at 4 °C for 1 h with 2 mmol/L chloramine T (Sigma Aldrich, Vienna, Austria), which oxidizes protein Met residues into corresponding sulfoxides \[[@R35]\] as well as modifies free SH groups \[[@R36]\]. Chloramine T was removed by gel filtration on Sephadex PD-10 columns (GE Healthcare, Munich, Germany).

2.16. Analyses of apo A-I Met residues by proteomics {#S18}
----------------------------------------------------

CuCl~2~-oxidized LDL (50 μg) was incubated with EV-HDL or EL-HDL (both 50 μg, three biological replicates each) for 30, 75 and 120 min at 37 °C, followed by termination of the reaction with acetone and detection of oxidized apoA-I Met residues by proteomics. For tryptic digest, 50 μg of HDL protein was precipitated with 4 volumes of acetone at −20 °C overnight, solubilized in 50 μL 100 mmol/L ammonium bicarbonate, reduced with 50 μL of 10 mmol/L DTT for 20 min under shaking at 550 rpm at 56 °C and alkylated with 50 μL of 60 mmol/L iodoacetamide under shaking at 550 rpm at RT for 15 min. Protein was digested by adding 1 μg modified trypsin (Promega) and shaking overnight at 550 rpm at 37 °C. The resulting peptide solution was acidified by adding 3 μL of 5% formic acid. Thereafter, 250 ng of the digest was injected and concentrated on the enrichment column (C18, 5 μm, 100 Å, 5 × 0.3 mm) for 2 min using 0.1% formic acid as isocratic solvent at 5 μL/min flow rate. The column was then switched in the nanoflow circuit and the sample was loaded on the nanocolumn (Acclaim PepMap RSLC nanocolumn; C18, 2 μm, 100 Å, 500 × 0.075 mm), at a flow rate of 250 nL/min at 60 °C and separated using the following gradient: solvent A: water, 0.1% formic acid; solvent B: acetonitrile, 0.1% formic acid; 0--2 min: 4% B; 2--90 min: 4--25% B; 90--95 min: 25--95% B, 96--110 min: 95% B; 110--110.1 min: 4% B; 110.1--125 min: 4% B. The sample was ionized in the nanospray source equipped with stainless steel emitters (Thermo Fisher Scientific, Vienna, Austria) and analyzed in a Thermo Orbitrap velos Pro mass spectrometer in positive ion mode by alternating full scan MS (*m*/*z* 300 to 2000, 60,000 resolution) in the ICR cell and MS/MS by CID of the 20 most intense peaks in the ion trap with dynamic exclusion enabled. The LC-MS/MS data were analyzed by searching the human Swiss-Prot protein database containing all common contaminants with Proteome Discoverer 1.4 (Thermo Fisher Scientific) and Mascot 2.4.1 (MatrixScience, London, UK). Carbamidomethylation of cysteine residues was entered as fixed and methionine oxidation as well as cysteine sulfonation as variable modification. Detailed search criteria were used as follows: trypsin; max. Missed cleavage sites: 2; search mode: MS/MS ion search with decoy database search included (false discovery rate \< 1%); precursor mass tolerance ± 10 ppm; product mass tolerance ± 0.7 Da. Label free quantitation of precursor ions was done with Proteome Discoverer 1.4 (Thermo Fisher Scientific) to determine peptide intensities. ApoA-I peptides with detected oxidative modifications as well as their unmodified counterparts were relatively quantified and normalized on apoA-I total protein intensity, which was calculated by summing up all individual apoA-I peptide intensities for each sample. Overall 51 different peptides of apoA-I were detected. Values at time point zero were subtracted.

2.17. Statistical analyses {#S19}
--------------------------

Data are represented as the means + standard error of mean (S.E.M.). Statistical significance between two groups was determined by two-tailed unpaired *t*-test followed by Bonferroni correction for multiple testing. Comparisons among multiple groups were performed using one-way analysis of variance (ANOVA), with the Bonferroni post hoc test to determine *p* values. Statistical analyses were performed using Graph Pad Prism 5.0. software (GraphPad Software, La Jolla, CA, USA). Statistically significant differences between groups are indicated by *P*-values of \< 0.05 (\* or \#), \< 0.01 (\*\* or \#\#), or \< 0.001 (\*\*\* or \#\#\#).

3. Results {#S20}
==========

3.1. EL alters structure and size of HDL {#S21}
----------------------------------------

To study the impact of EL on the antioxidative capacity of HDL, we prepared EL-modified HDL and control HDL by incubating isolated HDL with EL- and EV-overexpressing HepG2 cells ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}), followed by re-isolation of EL-HDL and EV-HDL by ultracentrifugation and subsequent purification by FPLC. As revealed by non-denaturing gradient-gel electrophoresis and subsequent protein staining, EL-HDL particles were smaller compared to EV-HDL ([Fig. 1A](#F1){ref-type="fig"}). This result was further confirmed by electron microscopy, showing greater abundance of small (0 nm--10 nm), and lower abundance of large (10 nm--15 nm) particles in the population of EL-HDL compared to EV-HDL particles ([Fig. 1B, C](#F1){ref-type="fig"}). Impact of EL on the size and structure of HDL was assessed by SAXS analysis which showed a mean diameter of 133 Ǻ for EL-HDL, compared to 150 Ǻ for EV-HDL ([Fig. 1D](#F1){ref-type="fig"}). Furthermore, SAXS analysis revealed an increased distance distribution P(R) between 20 and 40 Ǻ for EL-HDL, indicating decreased lipid content. In addition, EL-HDL exhibited decreased maximal spatial dimension, exemplified by reduced density distribution *R* \> 80 Ǻ and maximal diameter (D~max~), respectively ([Fig. 1E](#F1){ref-type="fig"}).

3.2. EL-HDL exhibits altered lipid composition {#S22}
----------------------------------------------

Considering the established relationship between HDL lipid composition and the antioxidative capacity of HDL, we examined lipid composition of purified EV-HDL and EL-HDL. As revealed by MS analyses ([Table 1](#T1){ref-type="table"}), the levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), triacylglycerol (TAG), and diacylglycerol (DAG) were significantly decreased, whereas the levels of lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), FA, and ceramide (Cer) were significantly increased in EL-HDL when compared to EV-HDL. The levels of free cholesterol (FC) showed a trend to be higher in EL-HDL compared to EV-HDL, however, the *p*-values were no longer significant after Bonferroni correction for multiple comparison. Cholesterol ester (CE) and sphingomyelin (SM) content were not significantly different between EL-HDL and EV-HDL.

3.3. EL modification reduces HDL-associated enzymes {#S23}
---------------------------------------------------

As revealed by Western blotting analyses, the abundance of HDL-associated enzymes, known to contribute to the antioxidative capacity of HDL, such as PON1 ([Fig. 2A](#F2){ref-type="fig"}), LCAT ([Fig. 2B](#F2){ref-type="fig"}) and PAF-AH ([Fig. 2C](#F2){ref-type="fig"}),was significantly lower in EL-HDL when compared to EV-HDL.

3.4. EL-HDL exhibits increased antioxidative capacity {#S24}
-----------------------------------------------------

Next, we studied the capacity of EL-HDL to protect LDL from copper ion-induced oxidation as well as its resistance to copper ion-induced oxidation in the absence of LDL. Importantly, EL-HDL dose dependently attenuated LDL oxidation as illustrated with the longer lag phases (significant at the two highest EL-HDL concentrations) and lower MDA concentrations (significant at the highest EL-HDL concentrations) in the presence of EL-HDL compared to LDL alone ([Fig. 3C, D](#F3){ref-type="fig"}). Oppositely, EV-HDL promoted LDL oxidation as exemplified by unaltered lag phases (except in the presence of highest EV-HDL concentration) and significantly higher MDA levels (at the two highest EV-HDL concentrations) compared to LDL alone ([Fig. 3C, D](#F3){ref-type="fig"}). Although the lag phase for the cooper ion-induced oxidation of EV-HDL and EL-HDL in the absence of LDL could not be calculated, the traces in [Fig. 3A and B](#F3){ref-type="fig"} clearly show a slower formation of conjugated dienes in EL-HDL compared to EV-HDL. In line, in the absence of LDL, the MDA levels were significantly lower in EL-HDL compared to EV-HDL ([Fig. 3D](#F3){ref-type="fig"}). Together, EL-modification of HDL increases the resistance of HDL to copper ion-induced oxidation and the capacity of HDL to protect LDL from copper ion-induced oxidation.

3.5. Depletion of lipolytic products abolishes capacity of EL-HDL to protect LDL from copper ion-induced oxidation {#S25}
------------------------------------------------------------------------------------------------------------------

Because the action of EL on HDL markedly increases the content of lipolytic products in HDL ([Table 1](#T1){ref-type="table"}), we hypothesized that the accumulated lipolytic products might be responsible for the augmented antioxidative capacity of EL-HDL. To test this hypothesis, we depleted lipolytic products in EL-HDL and EV-HDL by performing HDL modification in the presence of 4% BSA followed by purification of HDL by ultracentrifugation and FPLC. As revealed by Western blotting using an antibody which detects both human albumin and BSA, purified EV-HDL and EL-HDL were free of plasma albumin and BSA [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). This procedure markedly decreased the LPC ([Fig. 4A](#F4){ref-type="fig"}), FA ([Fig. 4B](#F4){ref-type="fig"}), and LPE ([Supplementary Fig. S3F](#SD1){ref-type="supplementary-material"}), without significantly affecting the content of other lipids ([Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}) in EV-HDL and EL-HDL. Importantly, depletion of lipolytic products abolished the capacity of EL-HDL to protect LDL from copper ion-induced oxidation; the lag phases were shorter or similar compared to that of LDL alone (except in the presence of 100 μg/mL EL-HDL) ([Fig. 4C](#F4){ref-type="fig"}) and the MDA levels were significantly higher compared to LDL alone ([Fig. 4D](#F4){ref-type="fig"}). This finding is in sharp contrast to the results with EL-HDL prepared in the absence of BSA, thus containing high levels of lipolytic products (compare [Fig. 4C, D](#F4){ref-type="fig"} with [Fig. 3C, D](#F3){ref-type="fig"}). In contrast to EL-HDL, the capacity of EV-HDL to protect LDL from copper ion-induced oxidation was not affected by the depletion of lipolytic products; the duration of lag phases and MDA levels were similar as observed for EV-HDL which was prepared in the absence of BSA (compare [Fig. 4C, D](#F4){ref-type="fig"} and [Fig. 3C, D](#F3){ref-type="fig"}). In line with the presented results, depletion of lipolytic products diminished the difference between EV-HDL and EL-HDL regarding the duration of lag phase and MDA levels. This is illustrated by higher lag phase ratios (significant at 12.5 and 50 μg/mL HDL) as well as lower MDA ratios (at the highest HDL concentrations) of EV-HDL and EL-HDL prepared in the presence (w/ BSA) compared to the ratios of EV-HDL and EL-HDL prepared in the absence of BSA (w/o BSA) ([Fig. 4E, F](#F4){ref-type="fig"}). Furthermore, the resistance of EL-HDL to copper ion-induced oxidation in the absence of LDL was not significantly altered upon depletion of lipolytic products. The amounts of generated MDA and the difference in MDA content between EV-HDL and EL-HDL ([Fig. 4D](#F4){ref-type="fig"}) were similar to what we found with EV-HDL and EL-HDL prepared in the absence of BSA ([Fig. 3D](#F3){ref-type="fig"}). Together, depletion of lipolytic products abolished the capacity of EL-HDL to protect LDL from copper ion-induced oxidation without affecting the resistance of EL-HDL to copper ion-induced oxidation.

3.6. LPC enrichment partially restores the capacity of lipolytic products-depleted EL-HDL to protect LDL from copper ion-induced oxidation {#S26}
------------------------------------------------------------------------------------------------------------------------------------------

To substantiate the role of lipolytic products in the antioxidative capacity of EL-HDL, we enriched the lipolytic products-depleted EL-HDL (and EV-HDL) with LPC 16:0 or LPC 18:1 ([Fig. 5A](#F5){ref-type="fig"}). Enrichment of the lipolytic products-depleted EL-HDL with LPC 18:1 markedly improved the capacity of that HDL to protect LDL from oxidation. This is exemplified by significantly longer lag phases at the two highest HDL concentrations and significantly lower MDA concentrations at all tested LPC-enriched HDL concentrations when compared to the lipolytic products-depleted EL-HDL ([Fig. 5B, C](#F5){ref-type="fig"}). Enrichment of the lipolytic products-depleted EL-HDL with LPC 16:0 did not affect the lag phase duration ([Fig. 5B](#F5){ref-type="fig"}), but significantly attenuated MDA formation when compared to the lipolytic products-depleted EL-HDL ([Fig. 5C](#F5){ref-type="fig"}). The resistance of EL-HDL to copper ion-induced oxidation (in the absence of LDL) was not significantly affected by LPC enrichment ([Fig. 5C](#F5){ref-type="fig"}). Enrichment of the lipolytic products-depleted EV-HDL with LPC 16:0 or LPC 18:1 significantly prolonged the lag phase ([Fig. 5D](#F5){ref-type="fig"}) but had no impact on the rate of MDA formation ([Fig. 5E](#F5){ref-type="fig"}). Together, LPC enrichment partially restores the diminished capacity of lipolytic products-depleted EL-HDL to protect LDL from copper ion-induced oxidation.

3.7. Role of apoA-I Met residues and chloramine T-sensitive antioxidative activities {#S27}
------------------------------------------------------------------------------------

Previous studies have shown that HDL size and structure affect conformation of HDL-associated proteins, resulting in altered accessibility and in turn altered antioxidative activity of Met residues and free-SH groups \[[@R1],[@R3]\]. We therefore investigated the contribution of apoA-I Met residues to the antioxidative capacity of EL-HDL. For this purpose, purified EV-HDL and EL-HDL were incubated in the absence or presence of copper oxidized LDL at 37 °C for up to 120 min. We detected higher levels of apoA-I Met136 sulfoxides (contained in the peptide WQEEM (136)ELYR) in EL-HDL compared to EV-HDL (*P* = 0.028), however, upon Bonferroni correction for multiple comparison this difference did not remain statistically significant ([Fig. 6A](#F6){ref-type="fig"}). The levels of other apoA-I Met sulfoxides were not significantly different (before and after Bonferroni correction) or not sufficiently covered in EV-HDL and EL-HDL (not shown). Incubation of EV-HDL and EL-HDL in the absence of oxidized LDL resulted in very low and similar levels of apoA-I sulfoxides in both HDL types (not shown).

To address the role of Met residues (and free SH groups) in the antioxidative capacity of EL-HDL, we examined the antioxidative capacity of chloramine T (oxidizes Met residues to the respective sulfoxides and modifies free thiols)-treated EV-HDL and EL-HDL \[[@R3],[@R36]\]. As revealed by proteomics, 85--90% of apoA-I Met residues in EV-HDL and EL-HDL were oxidized following chloramine T treatment. Chloramine T abolished the capacity of both EV-HDL and EL-HDL to protect LDL from oxidation exemplified by significantly shorter lag phases and significantly higher MDA levels in the presence of EV-HDL or EL-HDL compared to LDL alone ([Fig. 6B, C](#F6){ref-type="fig"}). Chloramine T did not alter the difference between EV-HDL and EL-HDL in terms of the duration of the lag phase (compare [Fig. 6B](#F6){ref-type="fig"} and [Fig. 3C](#F3){ref-type="fig"}) as illustrated through the similar lag phase ratios ([Fig. 6D](#F6){ref-type="fig"}). In contrast, however, chloramine T-treatment of HDL diminished the difference in MDA levels between EV-HDL and EL-HDL (compare [Fig. 6C](#F6){ref-type="fig"} with [Fig. 3D](#F3){ref-type="fig"}), resulting in a lower MDA ratios of chloramine T-treated compared to chloramine T-untreated EV-HDL and EL-HDL, which upon Bonferroni correction for multiple comparison did not remain significant ([Fig. 6E](#F6){ref-type="fig"}). The oxidation of EV-HDL and EL-HDL in the absence of LDL was not affected by chloramine T as the MDA levels were similar in chloramine T-treated compared to untreated EV-HDL and EL-HDL (see also [Fig. 6C](#F6){ref-type="fig"} and [3D](#F3){ref-type="fig"}). This is further exemplified by the similar MDA ratio of chloramine T-treated *versus* untreated EV-HDL to EL-HDL, respectively ([Fig. 6E](#F6){ref-type="fig"}). From these results we concluded that the chloramine T-sensitive anti-oxidative mechanisms contribute to the capacity of EL-HDL to protect LDL from copper ion-induced oxidation without affecting the resistance of EL-HDL to copper ion-induced oxidation in the absence of LDL.

3.8. Antioxidative capacity -- role of HDL particle size {#S28}
--------------------------------------------------------

Considering established inverse relationship between HDL size and its antioxidative capacity \[[@R37]\], the augmented antioxidative capacity of EL-HDL may (at least in part) be due to its smaller size. Accordingly, the smallest particles may exhibit the highest antioxidative capacity. We therefore prepared different sized fractions of EL-HDL and EV-HDL by FPLC ([Suppl. Fig. S4A](#SD1){ref-type="supplementary-material"}) and tested their capacity to protect LDL from copper ion-induced oxidation as well as their sole effect on resistance to copper ion-induced oxidation. We observed a trend of a negative relationship between EL-HDL particle size and the capacity to protect LDL from copper ion-induced oxidation (large *versus* small particle size - [Suppl. Fig. S4B, C](#SD1){ref-type="supplementary-material"}). However, the opposite was found for EV-HDL (large *versus* small particle size - [Suppl. Fig. S4D, E](#SD1){ref-type="supplementary-material"}). Interestingly, both small EV-HDL and small EL-HDL particles exhibited significantly higher resistance to copper ion-induced oxidation in the absence of LDL, when compared to respective large particles ([Suppl. Fig. S4C, E](#SD1){ref-type="supplementary-material"}). The increased antioxidative capacity of small compared to large EV-HDL and EL-HDL particles was accompanied by significantly lower PI, TAG, FC, Cer, and SM contents in small EV-HDL ([Suppl. Fig. S5](#SD1){ref-type="supplementary-material"}) as well significantly lower TAG, FC, and Cer contents in small EL-HDL ([Suppl. Fig. S6](#SD1){ref-type="supplementary-material"}) compared to the respective large HDL particles. Interestingly, LPC content was similar in the different sized fractions of EV-HDL and EL-HDL ([Suppl. Fig. S5 and S6](#SD1){ref-type="supplementary-material"}).

3.9. Comparison of structural and functional features of native HDL (nHDL) with EV-HDL and EL-HDL {#S29}
-------------------------------------------------------------------------------------------------

To examine whether and how modified HDL differ from native nHDL, we compared structural and functional features of EV-HDL and EL-HDL with nHDL isolated from human plasma by ultracentrifugation and further purified by FPLC. As revealed by non-denaturing gradient-gel electrophoresis nHDL particles were larger compared to EV-HDL and EL-HDL ([Supplementary Fig. S7A](#SD1){ref-type="supplementary-material"}). SAXS-derived low-resolution models showed a mean diameter of 160 Ǻ for nHDL compared to 150 Ǻ for EV-HDL and 133 Ǻ for EL-HDL ([Supplementary Fig. S7B](#SD1){ref-type="supplementary-material"}). Furthermore, the SAXS data indicate that processing of nHDL to EV-HDL and even more to EL-HDL leads to a compaction of the particles and a decrease in the lipid content. This is exemplified by the lower distance distribution of nHDL in the region between 20 and 40 Ǻ compared to EV-HDL and EL-HDL, and a shift of the maximum from 90 Ǻ (nHDL) to 73 Ǻ (EV-HDL) and 65 Ǻ (EL-HDL) ([Suppl. Fig. S7C](#SD1){ref-type="supplementary-material"}). In line with SAXS data, the MS analyses revealed significantly higher PC, PE, PI, TAG, DAG, and SM levels in nHDL compared to EV-HDL and EL-HDL ([Supplementary Fig. S8](#SD1){ref-type="supplementary-material"}). Furthermore, LPC and LPE were similar in nHDL and EV-HDL and significantly lower compared to EL-HDL. The tested HDL contained similar levels of CE and Cer. Interestingly, the FC content of nHDL was significantly higher compared to EV-HDL but similar to that of EL-HDL. Moreover, while the content of LCAT and PAF-AH was higher in nHDL compared to EV-HDL, the content of PON1 was comparable in nHDL and EV-HDL ([Supplementary Fig. S9](#SD1){ref-type="supplementary-material"}). Despite structural and compositional differences between nHDL and EV-HDL, the resistance of nHDL to copper ion-induced oxidation and the capacity of nHDL to protect LDL from copper ion-induced oxidation were not significantly different from that of EV-HDL ([Supplementary Fig. S10](#SD1){ref-type="supplementary-material"}).

4. Discussion {#S30}
=============

Due to the fact that the capacity of HDL to protect LDL from oxidation is determined by structural features and composition of HDL \[[@R1]\], we hypothesized that EL (by altering structure and composition) \[[@R11],[@R16],[@R38]\] would markedly affect the antioxidative capacity of HDL. To test our hypothesis we modified HDL by incubation with EL-overexpressing cells and examined the antioxidative capacity of EL-modified HDL by monitoring its resistance to copper ion-induced oxidation as well as its capacity to attenuate copper ion-induced LDL oxidation.

In the present study, *in vitro* EL-modification markedly augmented the antioxidative capacity of HDL. This is in contrast to the observed increased antioxidative capacity of HDL isolated from EL-deficient mice \[[@R19]\]. It remains to be determined whether species-specific differences or differences between *in vivo* and *in vitro* models may explain the increasing effect of EL-overexpression and EL deficiency on HDL antioxidative capacity. However, one should bear in mind that the augmenting effect of EL deficiency on HDL antioxidative capacity was observed in one \[[@R19]\] but not another study \[[@R20]\].

In contrast to EL-modified HDL, both nHDL and EV-HDL promoted copper-ion induced LDL oxidation, highlighting the impact of EL-modification on the antioxidative capacity of HDL under the experimental conditions applied in the present study. Furthermore, the comparable magnitude of the copper-ion induced oxidation of LDL in the presence of nHDL or EV-HDL, excludes that the prooxidative feature of EV-HDL is due to the incubation of HDL with control HepG2 cells.

Previous studies have shown that small, dense HDL particles exhibit higher antioxidative capacity than larger, less dense particles \[[@R1]\]. Several mechanisms and molecular determinants including enrichment in LCAT, PAF-AH, and PON1, as well as the relative enrichment in apoA-I, altered apoA-I conformation, or altered lipid composition and packing of surface lipids were proposed to explain better antioxidative properties of small HDL particles \[[@R39]--[@R42]\]. Also the significantly higher resistance to copper ion-induced oxidation of small compared to large EL-HDL particles, suggests that the smaller size of EL-HDL contributes, at least in part, to its augmented antioxidative capacity when compared to EV-HDL. The lower content of LCAT, PAF-AH, and PON1 in EL-HDL argues against a significant contribution of these enzymes to the increased antioxidative capacity of EL-HDL. Furthermore, the lower content of LCAT and PAF-AH in EV-HDL compared to nHDL most probably reflects loss of these enzymes during incubation with HepG2 cells and/or during subsequent ultracentrifugation and FPLC purification.

A striking compositional feature of EL-HDL was its enrichment with LysoPL and FA. The depletion of lipolytic products from EL-HDL attenuated its capacity to protect LDL from copper ion-induced oxidation without affecting the resistance of EL-HDL to copper ion-induced oxidation in the absence of LDL. Conversely, the replenishment of the lipolytic products-depleted EL-HDL with LPC 16:0 or 18:1 improved but not completely restored the capacity of that HDL to protect LDL from oxidation. Although LPC 16:0 and 18:1 belong to the most abundant LPC species in EL-HDL \[[@R15]\], the replenishment of lipolytic products-depleted EL-HDL with single LPC species can hardly compensate for the BSA-mediated loss of a naturally occurring combination of LysoPL and FA found in EL-HDL \[[@R15]\]. Accordingly, only enrichment of HDL with a natural combination of lipolytic products as generated by the action of EL on HDL would probably fully restore the capacity of lipolytic products-depleted EL-HDL to protect LDL from oxidation.

Nevertheless, our results strongly indicate that the accumulation of EL-generated lipolytic products underlie the augmented capacity of EL-HDL to protect LDL from oxidation. It is likely that the presence of lipolytic products in EL-HDL increases the surface fluidity of HDL, thus facilitating the interaction of EL-HDL with oxidized LDL. The more profound restoration of EL-HDL\'s protective capacity upon enrichment with LPC 18:1, compared to LPC 16:0, likely reflects the superior effect of unsaturated compared to saturated LPC on the surface fluidity of HDL. Increased surface fluidity in turn may facilitate the transfer of LOOH from oxidized LDL to EL-HDL followed by conversion of LOOH to LOH by Met residues of apoA-I. Indeed, a previous study showed that LPC enrichment increases HDL surface fluidity \[[@R43]\] resulting in a decreased packing of surface lipids. This was accompanied by an augmented capacity of HDL to incorporate oxidation products including LOOH. Others, however, have shown that *in vitro* LPC enrichment reduced apoA-I content and the antioxidative capacity of HDL \[[@R44]\]. This suggests that the impact of LPC enrichment on the structural and functional properties of HDL is dependent on the structure and composition of HDL prior to enrichment. More specifically, the decreased content of phospholipids and lipolytic products in HDL is likely a prerequisite for the augmentation of HDL\'s antioxidative capacity by LPC enrichment. In line, in the present study LPC enrichment more profoundly augmented antioxidative capacity of the lipolytic products depleted EL-HDL compared to EV-HDL.

It is well documented that the antioxidative capacity of HDL is regulated by the abundance and conformation of apoA-I, whereby inactivation of LOOH by HDL is driven by apoA-I Met residues \[[@R3]\]. Incubation of EV-HDL and EL-HDL with oxLDL resulted in a trend of a higher oxidation rate of apoA-I Met136 in EL-HDL compared to EV-HDL, suggesting a more pronounced antioxidative activity of Met136 in apoA-I of EL-HDL. It is conceivable that the altered conformation of apoA-I, as a consequence of the EL-induced reduction in HDL particle size underlies the augmented antioxidative activity of apoA-I Met136 of EL-HDL. Additionally, an altered lipid content and composition of EL-HDL may facilitate the exposure of Met136 to the aqueous phase resulting in its augmented antioxidative capacity. In the present study, chloramine T profoundly attenuated the capacity of both EV-HDL and EL-HDL to protect LDL from oxidation. These findings indicate that the chloramine T-sensitive amino acids, primarily Met residues of apoA-I, but also free SH groups in other HDL associated proteins \[[@R1],[@R3]\], are important for the capacity of both EV-HDL and EL-HDL to protect LDL from oxidation. The fact that chloramine T diminished the difference between EL-HDL and EV-HDL regarding the capacity to protect LDL from oxidation, strongly suggests that chloramine T-sensitive mechanisms contribute to the better antioxidative capacity of EL-HDL. Interestingly, chloramine T did not affect the resistance of EV-HDL and EL-HDL to copper ion-induced oxidation in the absence of LDL, suggesting that different mechanisms are responsible for preventing HDL autooxidation and HDL-mediated protection of LDL from oxidation.

Enrichment of HDL surface lipids with FC, SM or Cer negatively affects the transfer of LOOH from LDL to HDL for subsequent reduction to inactive LOH by Met residues of apoA-I \[[@R1]\]. Accordingly, a higher content of FC and Cer in EL-HDL, is in contrast with the observed increased antioxidative capacity of EL-HDL. However, it is likely that accumulated lipolytic products by increasing the fluidity of the EL-HDL surface can counteract the augmented rigidity caused by FC and Cer. Indeed, higher resistance to copper ion-induced oxidation of small EV-HDL and small EL-HDL particles was accompanied by lower FC and Cer levels when compared to respective large HDL particles. Importantly, the small and large EV-HDL and EL-HDL particles did not differ in the abundance of LPC. This strongly suggests that the EL-generated lipolytic products enriched in EL-HDL may outperform the impact of FC and Cer on the antioxidative capacity of HDL. The content of several lipid species (including phospholipids, TAG, DAG, FC, and SM) was lower in EV-HDL compared to nHDL, indicating either a transfer of lipids to or degradation by HepG2 cells during modification. Interestingly, the FC levels of EL-HDL and nHDL were similar but significantly higher compared to EV-HDL ([Suppl. Fig. S8](#SD1){ref-type="supplementary-material"}). This finding possibly reflects a compensation of FC loss by an increased cholesterol efflux from EL-overexpressing HepG2 cells during *in vitro* HDL modification, similarly to results described in a previous study in EL-overexpressing macrophages \[[@R45]\].

The smaller size of EL-HDL compared to EV-HDL in consequence leads to higher EL-HDL particle numbers in antioxidative assays normalized to protein. Accordingly, the increased antioxidative capacity of EL-HDL observed in the present study may be a consequence of these higher EL-HDL particle numbers. However, the fact that lipolytic product depletion decreased both the antioxidative capacity ([Fig. 4](#F4){ref-type="fig"}) and size of EL-HDL ([Suppl. Fig. S11](#SD1){ref-type="supplementary-material"}) strongly indicates that enrichment with lipolytic products and not HDL particle numbers is the reason for the increase in antioxidative capacity of EL-HDL. Nevertheless, further experiments are required to elucidate the relative contribution of HDL particle numbers (size) to the increased antioxidative capacity of EL-HDL.

Considering results obtained by structural modeling of lipoprotein particles \[[@R42]\], one can speculate that the pronounced EL-induced perturbations in HDL size and composition promote the redistribution of CE to the HDL surface, leading to disturbed packing of surface lipids, which in turn may promote an efficient insertion of LOOHs (despite increased FC and Cer). Additionally, a recent study demonstrated a negative correlation between the TAG content of HDL and the HDL antioxidative capacity \[[@R46]\]. Accordingly, the decreased TAG levels might also contribute to the increased antioxidative activity of EL-HDL. Because the content of the minor PL species phosphatidylserine, which is a known enhancer of HDL functionality \[[@R37]\], could not be determined due to technical limitation, its contribution to antioxidative capacity of EL-HDL could not be addressed.

We have recently shown that EL diminishes cholesterol efflux capacity of HDL, which is the first step of reverse cholesterol transport, the best-studied atheroprotective activity of HDL \[[@R16]\]. This, together with EL-mediated augmentation of HDL\'s antioxidative capacity, which is also an important atheroprotective feature of HDL, may help understanding inconclusive data on the role of EL in atherosclerosis.

This study is not without limitations. First, the relative contribution of HDL particle concentration to the increased antioxidative capacity of EL-HDL could not be assessed. Our efforts to determine HDL particle concentrations in EV-HDL and EL-HDL preparations by nuclear magnetic resonance (NMR) spectroscopy failed. This is due to the fact that NMR spectroscopy allows quantification of HDL particles only in a physiological environment, full serum or plasma, but not in suspensions containing only HDL. Despite optimization of HDL purification procedure by FPLC, the albumin/BSA-free HDL was obtained in only 60--70% of preparations. Only the fractions which were, as revealed by Western blotting, free of albumin/BSA were used for antioxidative assays, whereas the preparations which after FPLC still contained residual albumin were used for SAXS or electron microscopy. Accordingly, there is some albumin and overlap of HDL with albumin in the preparations shown in [Fig. 1A](#F1){ref-type="fig"}, [Suppl. Fig. S7, or S11](#SD1){ref-type="supplementary-material"} but not in [Suppl. Fig. S2 and S4](#SD1){ref-type="supplementary-material"}, the latter two being representative of the preparations free of albumin/BSA used for functional assays. We cannot exclude that our albumin/BSA-free preparations also contain albumin/BSA, however, at concentrations which are below the detection limit of the applied Western blotting analyses. Furthermore, HDL was modified in the absence of serum and accordingly, in the presence of sub-physiological levels of HDL remodeling proteins which *in vivo*, together with EL, determine structural and functional properties of HDL \[[@R47],[@R48]\]. Additionally, we tested the impact of HDL on copper-ion induced oxidation of LDL which is only one out of several known mechanisms of LDL oxidation \[[@R49]\]. Accordingly, our results have limited capacity to predict impact of EL on the capacity of HDL to protect LDL from oxidation *in vivo*.

5. Conclusions {#S31}
==============

Here, we presented evidence that *in vitro* EL modification of HDL generates small HDL particles with altered composition and augmented antioxidative capacity. The augmented antioxidative capacity of EL-modified HDL is primarily due to the enrichment of HDL with EL-generated lipolytic products and to a lesser extent due to decreased HDL particle size and increased activity of chloramine T-sensitive mechanisms ([Fig. 7](#F7){ref-type="fig"}).
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![EL alters HDL size and structure.\
A) EV-HDL and EL-HDL were generated by incubation of human HDL with EV or EL overexpressing cells under cell culture conditions for 16 h. Thereafter, HDL was purified by ultracentrifugation and FPLC. 10 μg isolated HDL protein were electrophoresed on 4--20% non-denaturing polyacrylamide gels followed by Coomassie Brillant Blue staining. Protein size annotations refer to protein marker bands on the gel. B) Electron micrographs of EV-HDL and EL-HDL. Particle window size was 20 nm. C) Calculated particle size distribution. The number of analyzed particles was 1999 for EV-HDL and 1336 for EL-HDL. The data show abundance of sized EV-HDL and EL-HDL particles as percentage of the total number of analyzed particles. D) *Ab initio* shape models and E) pairwise distance distribution function of modified HDLs were generated by SAXS analysis and subsequent modeling.](EMS83891-f001){#F1}

![Abundance of PON1, LCAT and PAF-AH is decreased in EL-HDL.\
HDL proteins (10 μg/lane) were separated by 12% SDS-PAGE followed by Western blotting analyses of A) PON1, B) LCAT, and C) PAF-AH. Results show representative Western blots and corresponding densitometric analyses. Densitometric values of PON1, LCAT and PAF-AH were normalized to the corresponding apoA-I signals. Results obtained by densitometry are means + SEM of 4 independent modifications of human HDL, each loaded in duplicates and analyzed by two-tailed unpaired *t*-test. \*\*\**P* \< 0.001.](EMS83891-f002){#F2}

![EL increases the antioxidative capacity of HDL.\
Human LDL, EV-HDL and EL-HDL were incubated either individually or in the indicated combinations with 2 μmol/L CuCl~2~ at 37 °C followed by reaction termination after 120 min. The formation of conjugated dienes was monitored at 234 nm. Representative kinetic graphs of lipoprotein incubation with CuCl~2~ are shown in A) and B). C) The lag phase was determined with a simple sigmoid model. D) MDA levels were measured in the reaction mixture obtained after 120 min by HPLC. Results are means + SEM of 4 independent modifications of human HDL. The differences between EV-HDL and EL-HDL (with or without LDL) were analyzed by two-tailed unpaired *t*-test followed by Bonferroni correction for multiple comparison (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001) and between EV-HDL or EL-HDL (with or without LDL) and LDL alone by one-way ANOVA followed by Bonferroni post hoc test (^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001).](EMS83891-f003){#F3}

![Role of lipolytic products in the antioxidative capacity of EL-HDL.\
EV-HDL and EL-HDL were prepared in the absence (w/o BSA) or presence (w/ BSA) of 4% BSA followed by ultracentrifugation and FPLC. (A) LPC and (B) FA contents were determined by MS. LDL, EV-HDL and EL-HDL (the latter two prepared in the presence of 4% BSA) were incubated either individually or in the indicated combinations with 2 μmol/L CuCl~2~ at 37 °C followed by reaction termination after 120 min. (C) The formation of conjugated dienes was monitored at 234 nm. (D) MDA levels were measured in the reaction mixture obtained after 120 min by HPLC. (E) Lag phase and (F) MDA ratios of EV-HDL and EL-HDL prepared w/o or w/ 4% BSA. Results are means + SEM of 4 independent modifications of human HDL. The indicated differences in (A) and (B), as well as between EV-HDL and EL-HDL (with or without LDL) (C, D), and between w/o BSA and w/ BSA (E,F) were analyzed by two-tailed unpaired *t*-test followed by Bonferroni correction for multiple comparison (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). The differences between EV-HDL or EL-HDL (with or without LDL) and LDL (C, D) were analyzed by one-way ANOVA followed by Bonferroni post hoc test (^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001). w/o, without; w/, with;](EMS83891-f004){#F4}

![Impact of LPC enrichment on the antioxidative capacity of EL-HDL.\
(A) LPC content of EV-HDL and EL-HDL enriched or not with LPC 16:0 or 18:1 determined by MS. LDL, EV-HDL and EL-HDL (the latter two enriched or not with LPC) were incubated either individually or in the indicated combinations with 2 μmol/L CuCl~2~ at 37 °C followed by reaction termination after 120 min. (B,D) The formation of conjugated dienes was monitored at 234 nm. (C, E) MDA levels were measured after 120 min by HPLC. Results are means ± SEM of 4 independent modifications of human HDL. The differences in (A) were analyzed by two-tailed unpaired *t*-test followed by Bonferroni correction for multiple comparison. The differences between non-enriched and LPC-enriched EV-HDL or EL-HDL (with or without LDL) (B-E) (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001) as well as the differences between EV-HDL or EL-HDL (with or without LPC enrichment, with or without LDL) and LDL (B-E) (^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001) were analyzed by one-way ANOVA followed by Bonferroni post hoc test.](EMS83891-f005){#F5}

![Role of apoA-I Met residues and chloramine T-sensitive antioxidative activities.\
(A) CuCl~2~-oxidized LDL (50 μg) was incubated with EV-HDL or EL-HDL (50 μg) for 30, 75 and 120 min at 37 °C. ApoA-I Met sulfoxides were measured by proteomics. Human LDL, chloramine T-treated EV-HDL and EL-HDL were incubated either individually or in the indicated combinations with 2 μmol/L CuCl~2~ at 37 °C followed by reaction termination after 120 min. The formation of conjugated dienes was monitored at 234 nm. B) The lag phase was determined with a simple sigmoid model. C) MDA levels were measured in the reaction mixture obtained after 120 min by HPLC. Results in (A) are mean ± SEM of 3 independent modifications of human HDL and the differences between EV-HDL and EL-HDL at each indicated time-point were analyzed by two-tailed paired *t*-test followed by Bonferroni correction for multiple comparison. Results in B-E are means + SEM of 4 independent modifications of human HDL. The differences between EV-HDL and EL-HDL (with or without LDL) (B, C) and between w/o and w/ chloramine T (D, E) were analyzed by two-tailed unpaired *t*-test followed by Bonferroni correction for multiple comparison (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). The differences between EV-HDL or EL-HDL (with or without LDL) and LDL (B, C) were analyzed by one-way ANOVA followed by Bonferroni post hoc test (^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001).](EMS83891-f006){#F6}

![Consequences of EL action on HDL.\
*In vitro* EL action on HDL generates small HDL particles with altered lipid and protein composition and increased antioxidative activity.](EMS83891-f007){#F7}

###### MS analyses of EV-HDL and EL-HDL lipids.

  AU/mg HDL protein   EV-HDL          EL-HDL         p-value
  ------------------- --------------- -------------- ------------
  PC                  461.7 ± 19.39   172.1 ± 5.73   0.0001
  PE                  18.01 ± 0.35    3.53 ± 0.22     \< 0.0001
  PI                  156.0 ± 6.25    4.01 ± 0.13     \< 0.0001
  TAG                 51.67 ± 1.79    19.52 ± 1.91   0.0003
  DAG                 45.74 ± 1.52    11.88 ± 0.42    \< 0.0001
  LPC                 41.37 ± 0.68    108.2 ± 3.80    \< 0.0001
  LPE                 0.16 ± 0.004    0.19 ± 0.003   0.0033
  FA                  223.3 ± 6.78    1834 ± 222.1   0.0019
  FC                  0.95 ± 0.05     1.32 ± 0.05    0.0067
  CE                  1036 ± 16.06    1051 ± 102.0   0.8936
  Cer                 4.065 ± 0.10    5.229 ± 0.14   0.0025
  SM                  67.89 ± 2.24    75.17 ± 4.58   0.2265

Lipids from EV-HDL and EL-HDL (300 μg protein) purified by ultracentrifugation followed by FPLC were extracted and analyzed by MS. Results are mean ± SEM of 3 independent modifications of human HDL. The differences between EV-HDL and EL-HDL were analyzed by two-tailed unpaired *t*-test between EV- and EL-HDL. *P*-values of \< 0.004 are considered significant after a Bonferroni correction for multiple testing. PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; TAG, triacylglycerol; DAG, diacylglycerol; LPC, lysophosphatidylcholine, LPE, lysophosphatidylethanolamine, FC, free cholesterol, CE, cholesteryl ester; Cer, Ceramide; SM, Sphingomyelin; MS, mass spectrometry; SEM, standard error of mean;
